AbbVie ABBV continues to build momentum with its oncology franchise, with the recent FDA approval for Emrelis. This ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

The move marks a turning point in 23andMe’s tumultuous decline. Founded in 2006 by Wojcicki, the company initially gained traction with its saliva-based ancestry kits and went public in 2021. By the ...

Once a Silicon Valley pioneer in consumer genetic testing, 23andMe is now at the center of a high-stakes legal and financial ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Shares of the biotech Kymera Therapeutics are up 50% since Monday, when data from an early trial hinted that its pill might ...

Me is proposing to reopen its bankruptcy auction to entertain a final offer from a nonprofit operated by its co-founder, ...

After a brief court dispute, 23andMe and all its assets are up for auction once again. The second time around, former CEO Amy ...

Bankrupt genetic testing company 23andMe is looking to sell its assets — most notably its customers' DNA data — for more than ...

Added to that, 23andMe suffered a massive data breach in 2023 that resulted in information from about 7 million people being ...